Article Information
History
- November 13, 2017.
Article Versions
- You are currently viewing Version 1 of this article (November 13, 2017 - 14:13).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Rohan Khera, MD1*,
- Yuan Lu, ScD2*,
- Anshul Saxena, PhD3,
- Khurram Nasir, MD MPH3 and
- Harlan M. Krumholz, MD SM2,4
- 1Division of Cardiology, UT Southwestern Medical Center, Dallas, Texas
- 2Center for Outcomes Research and Evaluation, Yale-New Haven Health, New Haven, Connecticut
- 3Center for Healthcare Advancement and Outcomes, Baptist Health South Florida, Coral Gables, Florida
- 4Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine and the Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut
- Corresponding Author:
Dr. Harlan M. Krumholz; 1 Church St., Suite 200, New Haven, CT 06510 203-764-5885; harlan.krumholz{at}yale.edu
↵* Contributed equally.
Posted November 13, 2017.
The Impact of 2017 ACC/AHA Guidelines on the Prevalence of Hypertension and Eligibility for Anti-Hypertensive Therapy in the United States and China
